|
|
5941 Optical Court
San Jose, CA 95138 USA
phone:408-385-1742
fax:
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
2003 |
| Employees |
10 |
|
|
|
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Monoclonal Antibody Treatments for Pulmological Conditions |
|
| Management |
| Eric Patzer, President |
| |
|
|
| |
|
| Keywords |
| Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia. |
|
|
|
| Description |
|
Aridis is a development-stage company applying proprietary formulation and drug delivery technologies to the production of new monoclonal antibodies, protein therapeutics and vaccines targeting infectious diseases that significantly impact life expectancy. |
|
| Products / Services |
The Aridis product pipeline includes: a small molecule anti-infective compound which acts broadly against bacteria, viruses and fungi, oral vaccines to prevent infant and traveler's diarrhea from shigella infection, monoclonal antibodies for chronic lung infections associated with cystic fibrosis and an oral anthrax vaccine; all therapeutics can be conveniently administered orally or via inhalation.
|
|
| Market / Customers |
The company's initial products target infectious diseases that have a significant impact on life expectancy, such as infectious diseases in cystic fibrosis (CF), chronic obstructive pulmonary diseases (COPD), and ventilator associated pneumonia in adults and children.
|
|
| Status |
| Aridis is interested in partnership alliances at all stages of development, particularly with development partners working with thermally labile or fragile products, and seeks $7 million in Series A financing. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members